Insider Transactions in Q1 2022 at Ironwood Pharmaceuticals Inc (IRWD)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 24
2022
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,031
-2.8%
|
$36,372
$12.75 P/Share
|
|
Mar 15
2022
|
Catherine Moukheibir |
BUY
Grant, award, or other acquisition
|
Direct |
1,466
+1.85%
|
-
|
|
Mar 15
2022
|
Alexander J Denner |
BUY
Grant, award, or other acquisition
|
Direct |
1,152
+1.7%
|
-
|
|
Mar 14
2022
|
Julie Mc Hugh |
SELL
Open market or private sale
|
Direct |
20,000
-14.45%
|
$220,000
$11.67 P/Share
|
|
Mar 08
2022
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
248,869
+22.96%
|
-
|
|
Mar 02
2022
|
Minardo John Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,873
+31.48%
|
-
|
|
Mar 02
2022
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
81,448
+22.73%
|
-
|
|
Mar 02
2022
|
Ronald Silver Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,013
+19.78%
|
-
|
|
Mar 02
2022
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,498
+17.81%
|
-
|
|
Feb 28
2022
|
Jason Rickard SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
28,962
-1.68%
|
$289,620
$10.77 P/Share
|
|
Feb 28
2022
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
SELL
Open market or private sale
|
Direct |
17,607
-1.71%
|
$176,070
$10.77 P/Share
|
|
Feb 28
2022
|
Thomas A Mccourt Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
48,424
-1.96%
|
$484,240
$10.77 P/Share
|
|
Feb 28
2022
|
Ronald Silver Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,238
-1.19%
|
$22,380
$10.77 P/Share
|
|
Jan 19
2022
|
Thomas A Mccourt Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,290
+8.67%
|
-
|
|
Jan 19
2022
|
Jason Rickard SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,174
+9.22%
|
-
|
|
Jan 19
2022
|
Michael Shetzline CMO,SVP,Head-Res&Drug |
BUY
Grant, award, or other acquisition
|
Direct |
29,326
+12.1%
|
-
|